Authored By: Sarah
11 Jul 2024

 Car T-Cell Therapy Market to grow by USD 3027.1 million between 2024-2028

According to a research report “ Car T-Cell Therapy Market” by End-user (Hospitals, Cancer treatment centers) Type (CD19, CD22, BCMA, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 3027.1 million at a CAGR of  16.83% during the forecast period. In the rapidly evolving landscape of healthcare innovation, the Car T-Cell Therapy market is gaining significant traction. This is largely due to the development of "armored CARs," which interact with inflammatory cytokines like IL-15 and IL-12, enhancing the growth and longevity of CAR T cells during cancer-induced immune suppression. Governments are actively investing in this sector, funding research and development, establishing supportive legislation, and collaborating with private businesses to increase public awareness and accessibility to these transformative treatments. The National Cancer Institute (NCI) is a prime example of this commitment, allocating resources to both research and infrastructure development..

Browse market data tables, figures, and in-depth TOC on “Car T-Cell Therapy Market” by End-user (Hospitals, Cancer treatment centers) Type (CD19, CD22, BCMA, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.

 View detailed Table of Content- Click here

By End-user, the Hospitals segment is projected to dominate the market size in 2024.

The CD19 protein, expressed on B-cells, has revolutionized the cancer treatment landscape through CAR T-cell therapies. These innovative treatments, which involve genetically modifying T-cells to target CD19, have demonstrated significant success in combating B-cell malignancies, including B-ALL and DLBCL. For businesses in the immunotherapy sector, the CD19 CAR T-cell therapy market represents a lucrative opportunity, particularly for those addressing the unmet needs of chemotherapy-resistant patients with hematologic malignancies and solid tumors.

By Type, CD19  segment is expected to hold the largest market size for the year 2024.

In the global CAR T-cell therapy market landscape, hospitals emerge as the leading segment due to their pivotal role as key end-users. Hospitals provide essential infrastructure, medical expertise, and resources for CAR T-cell therapy administration. Specialized oncology departments or treatment centers within hospitals ensure eligible patients receive these advanced therapies. Healthcare professionals, including oncologists, hematologists, and nurses, oversee treatment processes, ensuring patient safety and monitoring therapy responses. Hospitals play a crucial role in patient identification for CAR T-cell therapy eligibility.

North America is forecasted to hold the largest market size by region in 2024.

The Car T-Cell Therapy Market represents a significant business opportunity in the healthcare sector, driven by advancements in immunotherapy and cellular technology. This market involves the production and application of chimeric antigen receptor (CAR) T-cells, genetically engineered immune cells, to target and eliminate cancer cells. Companies are investing heavily in research and development to bring innovative CAR T-cell therapies to market, addressing unmet medical needs and generating substantial revenue growth.

The Car T-Cell Therapy Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • ACROBIOSYSTEMS INC.
  • Allogene Therapeutics Inc.
  • Autolus Therapeutics plc
  • Bristol Myers Squibb Co.
  • Celyad Oncology SA
  • Eli Lilly and Co.
  • Fate Therapeutics Inc.
  • Fortress Biotech Inc.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services Inc.
  • Les Laboratoires Servier
  • Merck KGaA
  • Miltenyi Biotec B.V. and Co. KG
  • Noile Immune Biotech Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sangamo Therapeutics Inc
  • Sorrento Therapeutics Inc.
  • TCR2 Therapeutics Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

In the realm of precision medicine, Car T-cell therapies have emerged as a revolutionary approach to tailoring treatments for various cancer types, including lymphoma and leukemia. These therapies involve engineering a patient's own T-cells to recognize and attack cancer cells. Companies such as Celgene Corporation and Juno Therapeutics are at the forefront of this innovation in cancer treatment and blood cancer treatment. The prevalence of cancer in the patient population continues to rise, necessitating advancements in healthcare infrastructure and public awareness. Reimbursement policies are a critical factor in the market growth of Car T-cell therapies, as their high cost requires careful consideration. The incidence of cancer, particularly blood cancers, presents a significant opportunity for the Car T-cell therapy market to make a substantial impact on cancer treatments. Car T-cell therapies represent a promising development in the field of cancer treatment, offering a potential cure for some patients where traditional methods have failed. As research and development continue, we can expect to see further advancements and improvements in the efficacy and accessibility of these therapies.

Market Research Overview

The Car T-Cell Therapy market is a rapidly evolving sector in the healthcare industry, focusing on the development of innovative treatments for various hematologic malignancies, including Non-Hodgkin lymphoma and leukemia. Quality control measures are essential to ensure product consistency and cost-effectiveness in the production of these therapies. Car T-Cell Therapies, such as CAR T-cells from Celgene Corporation and TT-02 from Tessa Therapeutics, utilize genetic modification to enhance the immune system's ability to target and eliminate cancer cells. Immunotherapy, a patient-centric approach, has shown significant promise in the treatment of lymphoma and other indications. The prevalence of cancer, particularly blood cancer, continues to rise, necessitating the need for scalable and adaptive healthcare infrastructure to meet the growing patient population's demands. Clinical trials are ongoing to assess the safety and efficacy of Car T-Cell Therapies in solid tumors, such as ovarian cancer. Financial backing from investors and reimbursement policies are crucial factors influencing the market's growth. Innovations like CRISPR/Cas9 gene editing technology and Juno Therapeutics' CAR T-Cell Therapy are driving advancements in precision medicine, enabling the tailoring of treatments to individual patients. The incidence of cancer and the increasing awareness of cancer treatments among the public further fuel the market's expansion. Despite the challenges, the Car T-Cell Therapy market holds immense potential in revolutionizing cancer treatment and improving patient outcomes.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio